Content area
Full Text
The US Institute for Clinical and Economic Review (ICER) has released a Draft Evidence Report on the effectiveness and value on three drugs for the treatment of multiple myeloma: belantamab mafodotin [Blenrep; GlaxoSmithKline], ciltacabtagene autoleucel [cilta-cel; Johnson & Johnson, Legend Biotech Corp] and idecabtagene vicleucel [ide-cel; Bristol-Myers Squibb, bluebird bio]. These three drugs target the B-cell maturation antigen in heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM).
Blenrep was approved by the US FDA in August 2020 for the treatment of RRMM in patients who have previously received four or more lines of therapy....